Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board boosted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 20.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 167,100 shares of the medical equipment provider's stock after purchasing an additional 28,300 shares during the quarter. Canada Pension Plan Investment Board owned about 0.24% of Lantheus worth $14,949,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. MML Investors Services LLC lifted its holdings in shares of Lantheus by 24.6% during the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider's stock worth $476,000 after purchasing an additional 857 shares during the period. World Investment Advisors LLC acquired a new stake in shares of Lantheus in the 3rd quarter worth $60,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus in the third quarter valued at about $25,000. Tidal Investments LLC boosted its holdings in shares of Lantheus by 25.2% in the third quarter. Tidal Investments LLC now owns 17,621 shares of the medical equipment provider's stock valued at $1,934,000 after acquiring an additional 3,547 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Lantheus by 118.0% during the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider's stock worth $91,000 after acquiring an additional 551 shares during the period. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Stock Up 2.4 %

Shares of Lantheus stock traded up $2.44 on Thursday, hitting $103.64. The company's stock had a trading volume of 510,605 shares, compared to its average volume of 953,519. The firm has a fifty day moving average price of $97.01 and a 200-day moving average price of $95.38. Lantheus Holdings, Inc. has a 52-week low of $63.76 and a 52-week high of $126.89. The company has a market capitalization of $7.10 billion, a P/E ratio of 17.24 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares of the company's stock, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,109 shares of company stock valued at $6,016,046. Corporate insiders own 2.00% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent analyst reports. JMP Securities reiterated a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Finally, B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.